A Review of the Economic Evidence of Typhoid Fever and Typhoid Vaccines

K. Luthra, Elizabeth Watts, F. Debellut, C. Pecenka, Naor Bar-Zeev, Dagna Constenla

Research output: Contribution to journalArticle

Abstract

Typhoid places a substantial economic burden on low- and middle-income countries. We performed a literature review and critical overview of typhoid-related economic issues to inform vaccine introduction. We searched 4 literature databases, covering 2000-2017, to identify typhoid-related cost-of-illness (COI) studies, cost-of-delivery studies, cost-effectiveness analyses (CEAs), and demand forecast studies. Manual bibliographic searches of reviews revealed studies in the gray literature. Planned studies were identified in conference proceedings and through partner organization outreach. We identified 29 published, unpublished, and planned studies. Published COI studies revealed a substantial burden in Asia, with hospitalization costs alone ranging from $159 to $636 (in 2016 US$) in India, but there was less evidence for the burden in Africa. Cost-of-delivery studies are largely unpublished, but 1 study found that $671 000 in government investments would avert $60 000 in public treatment costs. CEA evidence was limited, but generally found targeted vaccination programs to be cost-effective. This review revealed insufficient economic evidence for vaccine introduction. Countries considering vaccine introduction should have access to relevant economic evidence to aid in decision-making and planning. Planned studies will fill many of the existing gaps in the literature.

Original languageEnglish (US)
Pages (from-to)S83-S95
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume68
Issue number2
DOIs
StatePublished - Mar 7 2019

Fingerprint

Typhoid-Paratyphoid Vaccines
Typhoid Fever
Economics
Costs and Cost Analysis
Cost of Illness
Vaccines
Cost-Benefit Analysis
Health Care Costs
India
Decision Making
Vaccination
Hospitalization
Organizations
Databases

Keywords

  • cost of illness
  • cost of vaccine delivery
  • cost-effectiveness analysis
  • typhoid fever
  • vaccination

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

@article{b8d7c519f3a140c69f3d00167af9765e,
title = "A Review of the Economic Evidence of Typhoid Fever and Typhoid Vaccines",
abstract = "Typhoid places a substantial economic burden on low- and middle-income countries. We performed a literature review and critical overview of typhoid-related economic issues to inform vaccine introduction. We searched 4 literature databases, covering 2000-2017, to identify typhoid-related cost-of-illness (COI) studies, cost-of-delivery studies, cost-effectiveness analyses (CEAs), and demand forecast studies. Manual bibliographic searches of reviews revealed studies in the gray literature. Planned studies were identified in conference proceedings and through partner organization outreach. We identified 29 published, unpublished, and planned studies. Published COI studies revealed a substantial burden in Asia, with hospitalization costs alone ranging from $159 to $636 (in 2016 US$) in India, but there was less evidence for the burden in Africa. Cost-of-delivery studies are largely unpublished, but 1 study found that $671 000 in government investments would avert $60 000 in public treatment costs. CEA evidence was limited, but generally found targeted vaccination programs to be cost-effective. This review revealed insufficient economic evidence for vaccine introduction. Countries considering vaccine introduction should have access to relevant economic evidence to aid in decision-making and planning. Planned studies will fill many of the existing gaps in the literature.",
keywords = "cost of illness, cost of vaccine delivery, cost-effectiveness analysis, typhoid fever, vaccination",
author = "K. Luthra and Elizabeth Watts and F. Debellut and C. Pecenka and Naor Bar-Zeev and Dagna Constenla",
year = "2019",
month = "3",
day = "7",
doi = "10.1093/cid/ciy1122",
language = "English (US)",
volume = "68",
pages = "S83--S95",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - A Review of the Economic Evidence of Typhoid Fever and Typhoid Vaccines

AU - Luthra, K.

AU - Watts, Elizabeth

AU - Debellut, F.

AU - Pecenka, C.

AU - Bar-Zeev, Naor

AU - Constenla, Dagna

PY - 2019/3/7

Y1 - 2019/3/7

N2 - Typhoid places a substantial economic burden on low- and middle-income countries. We performed a literature review and critical overview of typhoid-related economic issues to inform vaccine introduction. We searched 4 literature databases, covering 2000-2017, to identify typhoid-related cost-of-illness (COI) studies, cost-of-delivery studies, cost-effectiveness analyses (CEAs), and demand forecast studies. Manual bibliographic searches of reviews revealed studies in the gray literature. Planned studies were identified in conference proceedings and through partner organization outreach. We identified 29 published, unpublished, and planned studies. Published COI studies revealed a substantial burden in Asia, with hospitalization costs alone ranging from $159 to $636 (in 2016 US$) in India, but there was less evidence for the burden in Africa. Cost-of-delivery studies are largely unpublished, but 1 study found that $671 000 in government investments would avert $60 000 in public treatment costs. CEA evidence was limited, but generally found targeted vaccination programs to be cost-effective. This review revealed insufficient economic evidence for vaccine introduction. Countries considering vaccine introduction should have access to relevant economic evidence to aid in decision-making and planning. Planned studies will fill many of the existing gaps in the literature.

AB - Typhoid places a substantial economic burden on low- and middle-income countries. We performed a literature review and critical overview of typhoid-related economic issues to inform vaccine introduction. We searched 4 literature databases, covering 2000-2017, to identify typhoid-related cost-of-illness (COI) studies, cost-of-delivery studies, cost-effectiveness analyses (CEAs), and demand forecast studies. Manual bibliographic searches of reviews revealed studies in the gray literature. Planned studies were identified in conference proceedings and through partner organization outreach. We identified 29 published, unpublished, and planned studies. Published COI studies revealed a substantial burden in Asia, with hospitalization costs alone ranging from $159 to $636 (in 2016 US$) in India, but there was less evidence for the burden in Africa. Cost-of-delivery studies are largely unpublished, but 1 study found that $671 000 in government investments would avert $60 000 in public treatment costs. CEA evidence was limited, but generally found targeted vaccination programs to be cost-effective. This review revealed insufficient economic evidence for vaccine introduction. Countries considering vaccine introduction should have access to relevant economic evidence to aid in decision-making and planning. Planned studies will fill many of the existing gaps in the literature.

KW - cost of illness

KW - cost of vaccine delivery

KW - cost-effectiveness analysis

KW - typhoid fever

KW - vaccination

UR - http://www.scopus.com/inward/record.url?scp=85062644854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062644854&partnerID=8YFLogxK

U2 - 10.1093/cid/ciy1122

DO - 10.1093/cid/ciy1122

M3 - Article

C2 - 30845334

AN - SCOPUS:85062644854

VL - 68

SP - S83-S95

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 2

ER -